ELVN SCHEDULE 13G/A: SEC filing

Vestal Point Capital, LP

Filed with the SEC on · accession 0000902664-26-004579

ELVN filed a SCHEDULE 13G/A (schedule 13g/a) with the SEC on Nov 16, 2026. Vestal Point Capital, LP filed an amended Schedule 13G reporting beneficial ownership of 3,225,000 shares (4.4%) of Enliven Therapeutics common stock as of September 30, 2026. The stock moved -2.4% by the first close after the filing.

Summary of the filing

Vestal Point Capital, LP filed an amended Schedule 13G reporting beneficial ownership of 3,225,000 shares (4.4%) of Enliven Therapeutics common stock as of September 30, 2026. The filing is a passive investment disclosure under Rule 13d-1(b), with no stated intent to influence control.

Key details

Shares of common stock beneficially owned$3.2M
Percentage of class beneficially ownedPCT 4
Reporting person / beneficial owner (investment adviser)Vestal Point Capital, LP
Issuer / subject companyEnliven Therapeutics, Inc.
Chief investment officer and managing partner of vestal point capital, lpRyan Wilder

How ELVN stock reacted

Close before

$48.80

Nov 13, 2026

First close after

-2.42%

$47.62

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for ELVN, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for ELVN?

Click here

Frequently asked questions

What did ELVN file with the SEC on Nov 16, 2026?

ELVN filed a SCHEDULE 13G/A (SEC filing). Vestal Point Capital, LP filed an amended Schedule 13G reporting beneficial ownership of 3,225,000 shares (4.4%) of Enliven Therapeutics common stock as of September 30, 2026. The filing is a passive investment disclosure under Rule 13d-1(b), with no stated intent to influence control.

How do I read a SCHEDULE 13G/A?

A report the company filed with the SEC (the US market regulator). Start with the summary, then the key amounts and names. Compare it with the company’s earlier filings.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A SCHEDULE 13G/A (schedule 13g/a): A report the company filed with the SEC (the US market regulator).

How did ELVN stock react to this filing?

ELVN closed at $48.80 before the filing and $47.62 on Nov 16, 2026 (-2.42%).

Other ELVN SEC filings

Get alerts when ELVN files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days